Four Phase 3 clinical trials of baricitinib in the treatment of moderate-to-severe active rheumatoid arthritis enrolled patients who were methotrexate-naïve or had inadequate response to methotrexate, conventional disease-modifying antirheumatic drugs (DMARDs) or DMARDs with TNF inhibitors.
Based on the pathophysiological and clinical characteristics of N-ERD, anti-IL 5 therapy may be effective in this patient subgroup.
AAN 2016 General News
Treatment with oral dexamethasone for 4 days significantly improved pain levels in the majority of outpatients with status migrainosus, a retrospective chart review presented at the 68th AAN Annual Meeting has found.
ACR/ARHP Annual Meeting 2013
Exposure to glucocorticosteroids was associated with a significant increase in mortality, a finding that has "important implications for health care providers and people with arthritis," results of a population-based cohort study reported at the 2013 ACR/ARHP Annual Meeting.